Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...
EMA's CHMP issued a positive opinion for Novartis' Kisqali for high-risk early breast cancer. Kisqali showed a 25.1% reduced risk of cancer recurrence in Phase 3 NATALEE trial. The CHMP ...
“If approved, Kisqali could provide an effective and tolerable adjuvant treatment option to mitigate the risk of recurrence in a broader patient population, particularly for patients who ...
Esta afirmación, siguiendo la misma fuente, brinda objetivos prometedores para futuras investigaciones de nuevas sustancias bioactivas y fitoterapia y que brinden mayor evidencia científica.
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...
Aspectos positivos - Se han reportado resultados positivos de la Fase III para Kisqali y Fabhalta. - Se espera que la presentación de Pluvicto PSMAfore aumente significativamente la población de ...
Sigue en directo a través de FormulaTV el programa 'Ni que fuéramos Shhh' de Canal Quickie: con Belén Esteban, Kiko Matamoros, Lydia Lozano, Chelo García Cortés y Víctor Sandoval ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback